All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @xotorisocialss on TikTok · 256s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @xotorisocialss's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00It's five o'clock
  2. 0:03I'm so nervous even though I've done this before with semi-glutide and it didn't work for me
  3. 0:07So I'm hoping well this one is supposed to like tap help
  4. 0:12tackle like
  5. 0:14metabolic problems so
  6. 0:17So 50 units is what it's saying I'm here
  7. 0:23This oh it pops off so easily
  8. 0:26I'm nervous but I'm not nervous
  9. 0:32So I know people disinfected this area
  10. 1:02This is not my moment this feels like a lot now looking at it is crazy
  11. 1:20Fuck me, fuck me, fuck me, fuck me, fuck me, fuck me, fuck me
  12. 1:28Okay, I'm really out here doing doctor things
  13. 1:35God this feels weird
  14. 2:02Okay, period so
  15. 2:04We're good on that is what it seems
  16. 2:11All right
  17. 2:12We're cleaned
  18. 2:14Ready for the next one
  19. 2:16It really doesn't hurt that's interesting
  20. 2:22What's interesting though is that this semi-glutide one like it would sting after you put it in this one
  21. 2:31I'm not feeling anything
  22. 2:33Which is good I
  23. 2:36think oh
  24. 2:38My starting weight is
  25. 2:41291 I believe and yeah
  26. 2:47So let's see what happens that felt like a lot and
  27. 2:53I don't know but that's good. I'm glad
  28. 2:56Hopefully something happens it I
  29. 3:00Don't expect
  30. 3:02Anything I don't expect much for weight this month because it's only 2.5
  31. 3:10milligrams
  32. 3:11That what it is now milligrams 2.5 milligrams is what I'm taking right now
  33. 3:21and
  34. 3:24The person that recommended me this she didn't
  35. 3:29Like nothing happened the first month, but then her dose was up to so and then she started losing weight. So that's
  36. 3:38How I'm thinking it's gonna go
  37. 3:41a little see
  38. 3:43Shot not bad. It's a lot better than the semi-glutide in my personal opinion
  39. 3:49pain wise so
  40. 3:51516 just for reference on June 9
  41. 3:582025
  42. 4:00And yeah, so I'll talk to you guys
  43. 4:05When things start happening. I don't know and also definitely I'll be back for my weekly update my weekly shots

@xotorisocialss's tirzepatide journey claims, fact-checked

Tori || UGC + SMM 🎀

TikTok creator

18.3K viewsWatch on TikTok

Quick answer

The creator is initiating compounded tirzepatide at 2.5 mg weekly for weight management in the context of PCOS and Hashimoto's thyroiditis, both conditions associated with insulin resistance and impaired metabolic regulation. Her prior semaglutide experience suggests a history of GLP-1 receptor agonist use without adequate response, which is clinically relevant since tirzepatide's additional GIP receptor activity may offer a different metabolic mechanism. Whether she is under active physician supervision for dose titration and thyroid monitoring is unclear from the video.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @xotorisocialss's tirzepatide journey claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@xotorisocialss's tirzepatide journey claims, fact-checked" from Tori || UGC + SMM 🎀. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is initiating compounded tirzepatide at 2.

The reason this review is not generic is the source wording and the canonical claim label "glp1 stay tuned i ll keep updates throughout my journey and i m." In this clip, the useful excerpt is: "It's five o'clock I'm so nervous even though I've done this before with semi-glutide and it didn't work for me So I'm hoping well this one is supposed to like tap help tackle like metabolic problems so So 50 units is what it's saying I'm..." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide outperformed semaglutide on both weight and HbA1c in the SURPASS-2 head-to-head trial (Frias et al.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is initiating compounded tirzepatide at 2.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is initiating compounded tirzepatide at 2.5 mg weekly for weight management in the context of PCOS and Hashimoto's thyroiditis, both conditions associated with insulin resistance and impaired metabolic regulation. Her prior semaglutide experience suggests a history of GLP-1 receptor agonist use without adequate response, which is clinically relevant since tirzepatide's additional GIP receptor activity may offer a different metabolic mechanism. Whether she is under active physician supervision for dose titration and thyroid monitoring is unclear from the video.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produced up to 22.5% body weight loss over 72 weeks, making it among the most effective approved weight-loss medications currently available.
  • Tirzepatide outperformed semaglutide on both weight and HbA1c in the SURPASS-2 head-to-head trial (Frias et al., 2021, NEJM), which supports switching in patients who did not respond to semaglutide.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produced up to 22.5% body weight loss over 72 weeks, making it among the most effective approved weight-loss medications currently available.
  • Tirzepatide outperformed semaglutide on both weight and HbA1c in the SURPASS-2 head-to-head trial (Frias et al., 2021, NEJM), which supports switching in patients who did not respond to semaglutide.
  • Evidence for tirzepatide specifically improving PCOS outcomes is preliminary. A 2024 pilot study in Fertility and Sterility showed promise for androgen levels and insulin sensitivity, but larger trials are needed.
  • Compounded tirzepatide is not FDA-approved and cannot be assumed to be bioequivalent to brand-name Mounjaro or Zepbound. The FDA issued safety alerts about compounded GLP-1 products in 2024 citing dosing and purity concerns.
  • 2.5 mg weekly is the correct starting dose per approved labeling, but dose escalation should be supervised by a licensed provider, particularly in patients with thyroid conditions like Hashimoto's.
  • Hashimoto's thyroiditis can independently impair resting metabolic rate and complicate weight-loss drug response. Thyroid function should be actively monitored during any weight-loss intervention.
  • Self-dosing compounded tirzepatide without clear physician oversight, as this video appears to show, carries real risks including incorrect dosing, unmonitored side effects, and interactions with thyroid disease management.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @xotorisocialss actually say?

Filming her first tirzepatide injection at 5 a.m., the creator said she was switching from semaglutide because tirzepatide is "supposed to help tackle like metabolic problems." She disclosed a starting weight of 291 lbs, a 2.5 mg starting dose, and said she "doesn't expect much for weight this month" based on a friend's experience. She also noted tirzepatide stung less than semaglutide at the injection site.

Worth noting: the hashtags reference compounded tirzepatide, and she mentions a price of $516, which strongly suggests she's using a compounded product, not brand-name Zepbound or Mounjaro. She never said that explicitly, but it matters.

Does the science back this up?

The "metabolic problems" framing is imprecise but not wrong. Tirzepatide acts on both GIP and GLP-1 receptors, which gives it a different metabolic profile than semaglutide, and there is real emerging evidence it may be more effective for insulin-resistant conditions like PCOS.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% body weight reduction in adults with obesity over 72 weeks, outperforming semaglutide's results in comparable trials. A 2023 head-to-head trial (Frias et al., SURPASS-2) showed tirzepatide significantly outperformed semaglutide on HbA1c and weight in type 2 diabetes. For PCOS specifically, the evidence is thinner. A 2024 pilot study (Patel et al., Fertility and Sterility) suggested tirzepatide improved androgen levels and insulin sensitivity in women with PCOS, but sample sizes were small and this is far from settled science.

What did they get wrong (or right)?

She got the dose right, more or less. 2.5 mg is the standard starting dose for tirzepatide in clinical protocols, and her expectation of minimal weight loss in month one is consistent with how titration-based dosing works in practice. That's accurate.

Where she's imprecise: saying tirzepatide is "supposed to tackle metabolic problems" is vague enough to be misleading. GLP-1 and GIP receptor agonism does affect insulin signaling, lipid metabolism, and appetite regulation, but tirzepatide does not treat or cure PCOS or Hashimoto's thyroiditis. These are two distinct autoimmune and endocrine conditions that require medical management beyond any weight-loss drug. The creator does not make that stronger claim, to her credit, but viewers with these conditions may fill in that gap themselves.

Her injection technique commentary, disinfecting the site and observing reduced sting compared to semaglutide, is consistent with what clinical literature and patient-reported experience suggest about subcutaneous formulation differences.

What should you actually know?

If you have PCOS and Hashimoto's and are considering tirzepatide, there are three things worth knowing. First, compounded tirzepatide is not the same product as FDA-approved Mounjaro or Zepbound. The FDA has repeatedly flagged purity, potency, and dosing concerns with compounded GLP-1 products. Second, $516 per month without a titration plan from a licensed provider is a real risk. Dose errors with tirzepatide are not trivial, and the creator's casual "50 units is what it's saying" suggests she may be self-dosing from a compounding pharmacy instruction sheet rather than a physician-supervised protocol.

Third, the friend-based expectation-setting, "nothing happened the first month, then her dose went up," is anecdotal and variable. Individual response to tirzepatide depends on genetics, insulin resistance levels, thyroid function, and other factors. Hashimoto's in particular can affect metabolism in ways that complicate weight-loss drug response.

  • Compounded tirzepatide is not FDA-approved and has no guaranteed bioequivalence to brand-name versions
  • 2.5 mg is the correct starting dose per clinical protocols, but dose changes should involve a provider
  • PCOS may respond to GLP-1/GIP agonism, but evidence is still early-stage
  • Hashimoto's adds a metabolic variable that a single drug cannot fully address
  • Injection site disinfection and technique matter and she appears to have done this reasonably

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Tori || UGC + SMM 🎀 · TikTok creator

18.3K views on this video

Stay tuned, I’ll keep updates throughout my journey and I’m so excited to see what’s to come ✨ Starting weight: 291lbs #pcos #tirzepatide #hashimotosthyroiditis #tirzepatidecompound #tirzepatidejour

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide produced up?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produced up to 22.5% body weight loss over 72 weeks, making it among the most effective approved weight-loss medications currently available.

What does the video say about tirzepatide outperformed semaglutide on both weight?

Tirzepatide outperformed semaglutide on both weight and HbA1c in the SURPASS-2 head-to-head trial (Frias et al., 2021, NEJM), which supports switching in patients who did not respond to semaglutide.

What does the video say about evidence for tirzepatide specifically improving pcos outcomes?

Evidence for tirzepatide specifically improving PCOS outcomes is preliminary. A 2024 pilot study in Fertility and Sterility showed promise for androgen levels and insulin sensitivity, but larger trials are needed.

What does the video say about compounded tirzepatide?

Compounded tirzepatide is not FDA-approved and cannot be assumed to be bioequivalent to brand-name Mounjaro or Zepbound. The FDA issued safety alerts about compounded GLP-1 products in 2024 citing dosing and purity concerns.

What does the video say about 2.5 mg weekly?

2.5 mg weekly is the correct starting dose per approved labeling, but dose escalation should be supervised by a licensed provider, particularly in patients with thyroid conditions like Hashimoto's.

What does the video say about hashimoto's thyroiditis can independently impair resting metabolic rate?

Hashimoto's thyroiditis can independently impair resting metabolic rate and complicate weight-loss drug response. Thyroid function should be actively monitored during any weight-loss intervention.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Tori || UGC + SMM 🎀, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.